Medical devices, healthcare technology and the business of care
510(k) clearance · K260203

Fule Vertebroplasty Balloon Catheter

Beijing Fule Science & Technology Development Co., Ltd. · Decision date Aug 28, 2026

FDA DECISIONK260203

What did the FDA decide?

FDA records K260203 as a 510(k) premarket notification, with a decision dated Aug 28, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Aug 28, 2026

FDA source record

Regulatory record facts

Identifier
K260203
Regulatory pathway
510(k) premarket notification
Product code
HRX
Decision code
SESE
Decision date
Aug 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Arthroscope.

Product code
HRX
FDA device class
2

FDA decision timeline

  1. K260203 received

    Application receipt date recorded by FDA.

  2. K260203 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code HRX

Product / regulatory recordCompanyPathwayDecision dateSource
SurGenTec, LLC510(k) clearanceOct 14, 2026FDA
Nexus CMF, LLC510(k) clearanceOct 9, 2026FDA
Karl Storz SE & CO. KG510(k) clearanceAug 26, 2026FDA
Clarus Medical, LLC510(k) clearanceMay 26, 2026FDA
Spinal Simplicity510(k) clearanceApr 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Beijing Fule Science & Technology Development Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Beijing

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records